Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia

Authors not listed

Emory University · 2022

Abstract

The purpose of this study is to investigate whether a blood pressure medication, spironolactone, can be tolerated by older African American adults that have memory and thinking problems, also called mild cognitive impairment (MCI). This study will also investigate the effect of spironolactone on memory and thinking abilities as measured by performance on cognitive tests, which are tests that measure memory and thinking skills. Participants will take spironolactone or a placebo for one year and will have 4 to 5 study visits during the study period.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-08 MST

Cite this

APA
Anonymous. (2022). Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia. <em>Emory University</em>. https://clinicaltrials.gov/study/NCT04522739
Vancouver
Anonymous. Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia. Emory University. 2022.
BibTeX
@misc{anon2022Spiron, title = {Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia}, author = {Anonymous}, journal = {Emory University}, year = {2022}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings